DOV KADMON to Animals
This is a "connection" page, showing publications DOV KADMON has written about Animals.
Connection Strength
0.119
-
In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
Score: 0.010
-
Fenretinide therapy in prostate cancer: effects on tissue and serum retinoid concentration. J Clin Oncol. 2000 Nov 15; 18(22):3804-8.
Score: 0.010
-
Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
Score: 0.008
-
Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J Cell Biochem Suppl. 1992; 16H:122-7.
Score: 0.005
-
Imaging prostate derived tumors with PET and N-(3-[18F]fluoropropyl)putrescine. Int J Rad Appl Instrum B. 1990; 17(6):525-32.
Score: 0.005
-
Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer. Prostate Cancer Prostatic Dis. 2009; 12(3):301-9.
Score: 0.004
-
Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
Score: 0.004
-
Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res. 2008 Feb 01; 68(3):731-9.
Score: 0.004
-
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
Score: 0.004
-
alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor. J Urol. 1986 Oct; 136(4):944-8.
Score: 0.004
-
Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
Score: 0.003
-
Synthesis and uptake of no-carrier-added 1-[11C]putrescine into rat prostate. Int J Nucl Med Biol. 1985; 12(5):349-52.
Score: 0.003
-
Effect of estrogen and androgen administration on alpha-difluoromethylornithine-enhanced putrescine uptake by the rat prostate. Prostate. 1985; 6(4):343-9.
Score: 0.003
-
Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61.
Score: 0.003
-
Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003 Apr; 162(4):1241-8.
Score: 0.003
-
Difluoromethylornithine enhancement of putrescine uptake into the prostate: concise communication. J Nucl Med. 1982 Nov; 23(11):998-1002.
Score: 0.003
-
The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
Score: 0.003
-
Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol. 1982 Jun; 127(6):1238-42.
Score: 0.003
-
Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
Score: 0.003
-
In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol Ther. 2001 Apr; 3(4):500-6.
Score: 0.002
-
Interposition sural nerve grafting during radical retropubic prostatectomy. Urology. 2001 Feb; 57(2):211-6.
Score: 0.002
-
Effect of surgery and adjuvant chemotherapy on the R3327 MAT-Ly Lu tumor. Prostate. 1981; 2(3):299-307.
Score: 0.002
-
Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis. 2000; 18(5):429-38.
Score: 0.002
-
Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest. 1996 Apr; 74(4):747-60.
Score: 0.002
-
Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer. Oncogene. 1995 Mar 02; 10(5):869-79.
Score: 0.002
-
Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech. 1995 Mar 01; 30(4):333-41.
Score: 0.002
-
Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol. 1995; 13(6):324-8.
Score: 0.002
-
Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994 Mar; 134(3):1039-45.
Score: 0.002
-
Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993 Oct 01; 53(19):4461-5.
Score: 0.001
-
Transgenic models for the study of prostate cancer. Cancer. 1993 Feb 01; 71(3 Suppl):1165-71.
Score: 0.001
-
Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog. 1993; 7(3):165-79.
Score: 0.001
-
Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas. J Steroid Biochem Mol Biol. 1992 Sep; 43(1-3):79-85.
Score: 0.001
-
Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl. 1992; 16H:54-61.
Score: 0.001
-
Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog. 1992; 5(1):52-61.
Score: 0.001
-
Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol. 1991 Apr; 5(4):503-13.
Score: 0.001
-
Experimental oncogene induced prostate cancer. Cancer Surv. 1991; 11:55-71.
Score: 0.001
-
N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors. J Nucl Med. 1989 Jul; 30(7):1205-10.
Score: 0.001
-
2-[18F]fluoroputrescine: preparation, biodistribution, and mechanism of defluorination. Int J Rad Appl Instrum A. 1986; 37(7):607-12.
Score: 0.001
-
Inhibition of mouse bladder tumor proliferation by murine interferon-gamma and its synergism with interferon-beta. Cancer Res. 1984 Oct; 44(10):4377-81.
Score: 0.001
-
Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor. Cancer Res. 1984 Mar; 44(3):1034-40.
Score: 0.001
-
Growth inhibition of a prostate tumor by alpha-difluoromethylornithine and by cyclophosphamide. Cancer Lett. 1982 May-Jun; 16(1):71-79.
Score: 0.001
-
Inhibition of the R3327MAT-Lu prostatic tumor by diethylstilbestrol and 1,2-bis(3,5-dioxopiperazin-1-yl)propane. Cancer Res. 1982 Apr; 42(4):1390-4.
Score: 0.001
-
Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine. Prostate. 1982; 3(4):383-9.
Score: 0.001
-
Effect of high dose diethylstilbestrol and ICRF-159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor. Cancer Lett. 1981 Jul; 13(2):139-45.
Score: 0.001